AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under the 351(k) biosimilar pathway, today announced that its Board of Directors has approved a 1-for-72 reverse stock split of the company’s common stock. The reverse stock split aims to increase the stock price to meet the NYSE American LLC’s listing requirements.
The reverse stock split will take effect at 12:01 AM Eastern Time on February 26, 2025. On this date, AEON’s common stock will begin trading on the NYSE American on a post-split basis, maintaining the ticker symbol “AEON,” though it will have a new CUSIP number, [00791X 209].
The decision follows the approval of a proposal during AEON’s Special Meeting of Stockholders, held on February 24, 2025, which authorized a reverse stock split within a range of 1-for-5 to 1-for-150. The final ratio was set at 1-for-72. After the reverse stock split, stockholder ownership percentages will remain unchanged, except for fractional shares, which will be rounded up to the nearest whole share.
